94.78 +0.39 (0.41%)
After hours: 4:26PM EST
|Bid||25.96 x 800|
|Ask||94.48 x 1000|
|Day's range||94.18 - 96.17|
|52-week range||71.83 - 103.00|
|Beta (5Y Monthly)||1.30|
|PE ratio (TTM)||44.99|
|Forward dividend & yield||0.28 (0.29%)|
|1y target est||N/A|
PerkinElmer, Inc., (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that its GSP® Neonatal Creatine Kinase –MM (CK-MM) kit has received U.S. Food & Drug Administration (FDA) approval. This solution is the first commercially available assay for screening newborns affected by Duchenne muscular dystrophy (DMD).
NEW YORK, Feb. 08, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.